CureVac Statistics
Total Valuation
CureVac has a market cap or net worth of $1.21 billion. The enterprise value is $794.81 million.
| Market Cap | 1.21B |
| Enterprise Value | 794.81M |
Important Dates
The last earnings date was Friday, August 15, 2025, before market open.
| Earnings Date | Aug 15, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
CureVac has 225.17 million shares outstanding. The number of shares has increased by 0.25% in one year.
| Current Share Class | 225.17M |
| Shares Outstanding | 225.17M |
| Shares Change (YoY) | +0.25% |
| Shares Change (QoQ) | +3.20% |
| Owned by Insiders (%) | 5.56% |
| Owned by Institutions (%) | 18.72% |
| Float | 125.87M |
Valuation Ratios
The trailing PE ratio is 5.36.
| PE Ratio | 5.36 |
| Forward PE | n/a |
| PS Ratio | 2.02 |
| Forward PS | 33.14 |
| PB Ratio | 1.76 |
| P/TBV Ratio | 1.84 |
| P/FCF Ratio | 5.25 |
| P/OCF Ratio | 5.06 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 2.72, with an EV/FCF ratio of 3.44.
| EV / Earnings | 3.50 |
| EV / Sales | 1.33 |
| EV / EBITDA | 2.72 |
| EV / EBIT | 2.86 |
| EV / FCF | 3.44 |
Financial Position
The company has a current ratio of 6.17, with a Debt / Equity ratio of 0.06.
| Current Ratio | 6.17 |
| Quick Ratio | 5.89 |
| Debt / Equity | 0.06 |
| Debt / EBITDA | 0.14 |
| Debt / FCF | 0.18 |
| Interest Coverage | 589.30 |
Financial Efficiency
Return on equity (ROE) is 40.22% and return on invested capital (ROIC) is 28.53%.
| Return on Equity (ROE) | 40.22% |
| Return on Assets (ROA) | 23.77% |
| Return on Invested Capital (ROIC) | 28.53% |
| Return on Capital Employed (ROCE) | 38.16% |
| Revenue Per Employee | $609,909 |
| Profits Per Employee | $231,341 |
| Employee Count | 983 |
| Asset Turnover | 0.82 |
| Inventory Turnover | 52.72 |
Taxes
In the past 12 months, CureVac has paid $31.42 million in taxes.
| Income Tax | 31.42M |
| Effective Tax Rate | 12.14% |
Stock Price Statistics
The stock price has increased by +92.17% in the last 52 weeks. The beta is 2.53, so CureVac's price volatility has been higher than the market average.
| Beta (5Y) | 2.53 |
| 52-Week Price Change | +92.17% |
| 50-Day Moving Average | 5.43 |
| 200-Day Moving Average | 4.00 |
| Relative Strength Index (RSI) | 50.66 |
| Average Volume (20 Days) | 619,763 |
Short Selling Information
The latest short interest is 669,986, so 0.30% of the outstanding shares have been sold short.
| Short Interest | 669,986 |
| Short Previous Month | 741,686 |
| Short % of Shares Out | 0.30% |
| Short % of Float | 0.53% |
| Short Ratio (days to cover) | 0.81 |
Income Statement
In the last 12 months, CureVac had revenue of $599.54 million and earned $227.41 million in profits. Earnings per share was $1.01.
| Revenue | 599.54M |
| Gross Profit | 568.65M |
| Operating Income | 278.21M |
| Pretax Income | -297.84M |
| Net Income | 227.41M |
| EBITDA | 292.04M |
| EBIT | 278.21M |
| Earnings Per Share (EPS) | $1.01 |
Balance Sheet
The company has $461.19 million in cash and $42.32 million in debt, giving a net cash position of $418.87 million or $1.86 per share.
| Cash & Cash Equivalents | 461.19M |
| Total Debt | 42.32M |
| Net Cash | 418.87M |
| Net Cash Per Share | $1.86 |
| Equity (Book Value) | 688.63M |
| Book Value Per Share | 3.06 |
| Working Capital | 413.11M |
Cash Flow
In the last 12 months, operating cash flow was $239.67 million and capital expenditures -$8.27 million, giving a free cash flow of $230.97 million.
| Operating Cash Flow | 239.67M |
| Capital Expenditures | -8.27M |
| Free Cash Flow | 230.97M |
| FCF Per Share | $1.03 |
Margins
Gross margin is 94.85%, with operating and profit margins of 46.40% and 37.93%.
| Gross Margin | 94.85% |
| Operating Margin | 46.40% |
| Pretax Margin | 43.17% |
| Profit Margin | 37.93% |
| EBITDA Margin | 48.71% |
| EBIT Margin | 46.40% |
| FCF Margin | 38.52% |
Dividends & Yields
CureVac does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -0.25% |
| Shareholder Yield | -0.25% |
| Earnings Yield | 18.74% |
| FCF Yield | 19.03% |
Analyst Forecast
The average price target for CureVac is $6.83, which is 26.72% higher than the current price. The consensus rating is "Hold".
| Price Target | $6.83 |
| Price Target Difference | 26.72% |
| Analyst Consensus | Hold |
| Analyst Count | 3 |
| Revenue Growth Forecast (5Y) | -13.86% |
| EPS Growth Forecast (5Y) | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | |
| Graham Upside |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
CureVac has an Altman Z-Score of 3.51 and a Piotroski F-Score of 7.
| Altman Z-Score | 3.51 |
| Piotroski F-Score | 7 |